Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer

被引：0
作者：
Samuel Murray
Vasilios Karavasilis
Mattheos Bobos
Evangelia Razis
Savvas Papadopoulos
Christos Christodoulou
Paris Kosmidis
George Fountzilas
机构：
[1] BioMarker Solutions Ltd,Department of Molecular Oncology
[2] GeneKOR,Department of Medical Oncology
[3] “Papageorgiou” Hospital,Department of Pathology
[4] Aristotle University of Thessaloniki School of Medicine,First Department of Medical Oncology
[5] Aristotle University of Thessaloniki School of Medicine,Department of Pathology
[6] “Hygeia” Hospital,Second Department of Medical Oncology
[7] “Hygeia” Hospital,Second Department of Medical Oncology
[8] “Metropolitan” Hospital,undefined
[9] “Hygeia” Hospital,undefined
来源：
Journal of Experimental & Clinical Cancer Research | / 31卷
关键词：
Predictive; Somatic mutation; EGFR; Gefitinib; Erlotinib; Response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Stinchcombe, Thomas E.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (04)
  • [12] EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer
    Bartolotti, Marco
    Franceschi, Enrico
    Brandes, Alba Ariela
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1429 - 1435
  • [13] Adjuvant EGFR tyrosine kinase inhibitors for patients with resected EGFR-mutated non-small-cell lung cancer: a network meta-analysis
    Tian, Wentao
    Tan, Nuopei
    Ke, Jiawen
    Zou, Ji'an
    Liu, Xiaohan
    Pan, Yue
    Zeng, Yue
    Peng, Yurong
    Wu, Fang
    FUTURE ONCOLOGY, 2022, 18 (21) : 2695 - 2708
  • [14] Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors
    Dong, Song
    Zhang, Xu-Chao
    Cheng, Hua
    Zhu, Jian-Quan
    Chen, Zhi-Hong
    Zhang, Yi-Fang
    Xie, Zhi
    Wu, Yi-Long
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (05) : 707 - 716
  • [15] Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
    Li, Yang
    Ni, Yunfeng
    Lv, Feng
    Shi, Yan
    Chen, Yedan
    Wu, Xiaoying
    Pang, Jiaohui
    Huang, Long
    Shao, Yang
    Wang, Tao
    Min, Jie
    Song, Yang
    BMC MEDICINE, 2025, 23 (01):
  • [16] Pyrimidine derivatives as EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: A comprehensive review
    Kizhakkedath Ratheesh, Anandu
    Pottankottu Jayan, Ajay
    Presanna, Aneesh Thankappan
    Nirmala, Saiprabha Vijayakumar
    CHEMICAL BIOLOGY & DRUG DESIGN, 2022, 100 (04) : 599 - 621
  • [17] Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations
    Shah, Riyaz
    Lester, Jason F.
    CLINICAL LUNG CANCER, 2020, 21 (03) : E216 - E228
  • [18] EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer
    Kamel-Reid, S.
    Chong, G.
    Ionescu, D. N.
    Magliocco, A. M.
    Spatz, A.
    Tsao, M.
    Weng, X.
    Young, S.
    Zhang, T.
    Soulieres, D.
    CURRENT ONCOLOGY, 2012, 19 (02) : E67 - E74
  • [19] Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
    Gazdar, A. F.
    ONCOGENE, 2009, 28 : S24 - S31
  • [20] Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials
    Petrelli, Fausto
    Borgonovo, Karen
    Cabiddu, Mary
    Barni, Sandro
    CLINICAL LUNG CANCER, 2012, 13 (02) : 107 - 114
12345